Mandate

Vinge Advises Tech Data on the Acquisition of Scribona Assets

March 11, 2008

Vinge represents Tech Data in connection to the acquisition of Scribona’s assets in Sweden, Finland and Norway. The business deal, which was made official on March the 4th, is conditioned by the approval of Scribona’s shareholders, which annual general meeting will take place on the 29th of April, but also by the approval of the competition authority of the European Union.   

Tech Data is listed on NASDAQ and it is one of the world’s largest distributors of Information Technology, it has an estimated revenue of USD 23 billion. Scribona is listed on Small Cap on OMX Nordic Exchange and one of Sweden, Finland and Norway’s leading distributors of Information Technology products. Scribona’s revenue has an approximate value of SEK 8 billions. Tech Data will, by the acquisition, become the largest distributor of Information Technology in the Nordic countries.

Partners Ulf Sallnäs (M&A), Fredrik Dahl (Employment) and Johan Karlsson (Antitrust) joined by associates Martin Hall (M&A), Emma Olsson (Employment) as well as Peter Alstergren and economist Mattias Ganslandt (Antitrust) made up Vinge’s team.      

Related

Vinge has advised Course Corrected VC on the establishment of Course Corrected VC Fund II

Vinge has advised Course Corrected VC on the establishment and structuring of their second fund, Course Corrected VC Fund II (the “Fund”).
November 12, 2026

Vinge advises Svenska Handelsfastigheter in connection with the acquisition of the Tallen retail park in Falun

Vinge is advising Svenska Handelsfastigheter in connection with the acquisition of the Tallen retail park in Falun from Dalafast. The acquisition comprises four properties with a total of 23,200 square metres of retail space, which together constitute Tallen’s largest retail area.
November 11, 2026

Vinge advises Egetis Therapeutics in connection with ANI Pharmaceuticals’ public cash offer

On 5 November 2026, ANI Pharmaceuticals, Inc., a U.S. biopharmaceutical company listed on The Nasdaq Global Market, announced a recommended public cash offer to the shareholders of Egetis Therapeutics AB (publ) and to the holder of Egetis’ convertible loan and warrants to tender all shares, the convertible loan and the warrants in Egetis to ANI. The total value of the offer amounts to approximately SEK 5,304 million.
November 10, 2026